Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.
How this was made
The 30-second read
Why it matters
The most tradable elements are the disclosed cash runway into 2029, the magnitude/composition of collaboration revenue, and the updated start dates for key programs (KT-621 Phase III mid-2027; KT-579 Phase I results Q4 2026; KT-200 IND expected 2027).
Market read
Investors get a clearer view of funding runway and the schedule for multiple late-stage transitions, which can shift probability-weighted valuation for KYMR’s pipeline.
What to watch
Regulatory discussions for KT-621 Phase III initiation are a gating item, and the transcript emphasizes organizational growth and higher R&D spend that may pressure future burn despite cash reserves.
Background
Kymera’s Q2 2026 earnings call transcript covers financials, partnership milestone revenue, and updated clinical development timelines for its immunology degraders.
Ticker impact
Kymera reported $1.5B cash, $65M collaboration revenue, and updated KT-621/KT-579/KT-200 timelines on its Q2 2026 earnings call transcript.
Moderately positive near-term bias as investors price in longer runway and earlier enrollment/Phase III initiation timing.
Key disclosed datapoints include cash runway into 2029, milestone-driven collaboration revenue, and specific timing updates (KT-621 Phase III mid-2027, KT-621 AD late-2027, KT-579 Phase I results Q4 2026).
Market effects
Reinforces investor focus on immunology targeted protein degradation timelines and the importance of placebo-rate management in immunology trials.
No clear regional-specific impact beyond US-listed biotech sentiment.
Phase III planning across US, EU5, and Japan highlights global development execution risk and opportunity.
Counterpoint
Despite the cash runway and timeline acceleration, the company flags elevated placebo rates and expects no additional revenue this year, which can limit near-term valuation support.
Key entities
- companyKymera Therapeutics, Inc.
US-listed immunology-focused targeted protein degradation company reporting Q2 2026 results and updated clinical timelines.
- partnerGilead Sciences
Partner whose option exercise fee and CDK2 molecular glue option activity are referenced in collaboration revenue and KT-200 IND timing.
- partnerSanofi
Partner referenced for a $20M milestone payment and KT-485 clinical trial initiation.
